LUMN vs MSGS

Lumen Technologies exhibits severe financial distress, anchored by a critical Piotroski F-Score of 2/9 and a negative Price-to-Book ratio of -7.98, which indicates negative shareholders' equity. While the stock has experienced a speculative 1-year price surge of 143.4%, this is decoupled from fundamentals characterized by negative revenue growth (-8.70%) and negative profit margins (-14.02%). The absence of a Graham Number and the bearish technical trend (0/100) further underscore a high-risk profile. Current pricing ($8.69) sits above the analyst target price ($7.67), suggesting the stock is currently overvalued relative to its distressed state.

MSGS presents a stark contrast between strong market momentum and deteriorating fundamental health, anchored by a stable Piotroski F-Score of 5/9. While the stock has seen a 70.6% increase over the last year and maintains a 'Buy' analyst consensus, the valuation is extreme with a Forward P/E of 1765.28 and a negative Price/Book ratio of -28.15. Severe liquidity concerns are evident in the Current Ratio of 0.47, suggesting potential short-term funding pressures. The investment thesis relies entirely on growth expectations and asset value not captured in book equity, rather than current financial stability.